-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MPT-0118 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MPT-0118 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MPT-0118 in Solid Tumor Drug Details: MPT-0118 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MQ-710 in Extramammary Paget Disease (EMPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MQ-710 in Extramammary Paget Disease (EMPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MQ-710 in Extramammary Paget Disease (EMPD) Drug Details: MQ-710 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVGBM-1 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVGBM-1 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AVGBM-1 in Glioblastoma Multiforme (GBM) Drug Details:AVGBM-1 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG-1007 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG-1007 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG-1007 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: ALG-1007...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-2902 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-2902 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IMM-2902 in Gastroesophageal (GE) Junction Carcinomas Drug Details:IMM-2902 is under development...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AVGBM-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AVGBM-1 Drug Details AVGBM-1 is under development for the treatment of glioblastoma. The therapeutic...